CellCentric

📍 Cambridge, United Kingdom👥 21 employees💰 Last funded Feb 2017
Biotechnology🌐 cellcentric.com
Website LinkedIn
Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally. p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers. CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers). These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise have few alternatives.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in CellCentric?
CellCentric has 1 investors on record on gritt.io.
When did CellCentric last raise funding?
The most recent investment in CellCentric recorded on gritt.io was in February 2017.
What industry is CellCentric in?
CellCentric operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is CellCentric based?
CellCentric is headquartered in Cambridge, United Kingdom.